3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Dermatologic
1
Conditions
Vomiting
4
Nausea
3
Squamous Cell Carcinoma of Head and Neck
1
Melanoma
1
Gynecologic Cancer
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
51
Ipilimumab
50
Cyclophosphamide
43
Nivolumab
41
aldesleukin
30
Interleukin-2
23
Vemurafenib
20
fludarabine
19
Temozolomide
18
fludarabine phosphate
15
dabrafenib
15
trametinib
12
spartalizumab
10
Radiotherapy
10
Radiosurgery
10
Dacarbazine
10
CTLA-4 Antigen
10
cobimetinib
9
binimetinib
9
poly ICLC
7
encorafenib
7
Paclitaxel
7
atezolizumab
6
Introns
6
Biopsy
6
montanide ISA 51
5
Carboplatin
5
epacadostat
4
MART-1 Antigen
4
Interferon alpha-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Melanoma
×
fosaprepitant
×
Clear all
NCT01874119
2018-06-07
HDIL2/Emend
St. Louis University
Phase 2
Terminated
13 enrolled
7 charts